Overview

NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. This is because Novartis did not provide a complete evidence submission.  

Guidance development process

How we develop NICE technology appraisal guidance

This advice updates and replaces NICE technology appraisal guidance 567 on tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies, which was available through the Cancer Drugs Fund. People already having it will be able to continue until they and their doctor decide when best to stop.